Objective: To assess a selection of psychometric properties of the TRANSIT indicators. Design: Using medical records, indicators were documented retrospectively during the 14 months preceding the end of the TRANSIT study. Setting: Primary care in Quebec, Canada. Participants: Indicators were documented in a random subsample (n = 123 patients) of the TRANSIT study population (n = 759). Interventions: For every patient, the mean compliance to all indicators of a category (subscale score) and to the complete set of indicators (overall scale score) were established. To evaluate test-retest and inter-rater reliabilities, indicators were applied twice, two months apart, by the 
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Introduction
Although cardiovascular diseases (CVDs) are one of the leading causes of death worldwide, significant therapeutic gaps have been identified in the management of preventable risk factors such as hypertension, dyslipidemia, diabetes, tobacco use, physical inactivity and overweight/obesity [1] [2] [3] [4] . In recent years, knowledge translation for quality improvement in primary care has become a major concern both in North America and internationally. Changes at clinical, organizational and legislative levels are currently underway to improve healthcare quality. However, monitoring quality of care is impossible without reliable and valid indicators.
An indicator is a quantitative measure related to structure, processes or outcomes of care [5, 6] . Since many quality indicators for CVDs have not yet been published and indexed, only eight sets of indicators related to CVD prevention were identified in the literature [6] [7] [8] [9] [10] [11] [12] [13] (see Supplementary Table S1 ). While several teams [7-9, 11, 13] tested the acceptability and the feasibility of their indicators, none conducted a complete psychometric analysis in which every type of reliability and validity is assessed.
The TRANSIT (TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care) indicators were developed through a rigorous participatory process involving researchers, healthcare managers, clinicians, patients and family members (see Supplementary Methods). Such an involvement of the primary care community allowed the development of a wide range of indicators that take into account priorities for action and challenges such as the implementation of collaborative practices and the provision of appropriate support to lifestyle changes [12, 14] . To optimize the effectiveness of the TRANSIT indicators in quality improvement strategies, their psychometric properties need to be evaluated.
Conducting a complete psychometric analysis of a large set of indicators is time consuming and raises many challenges such as limited access to medical records, lack of fully computerized medical records, and clinicians' apprehension regarding the evaluation of their clinical practices. Therefore, the current study is an attempt at conducting the first component of a complete psychometric analysis that will lead towards the elaboration of a smaller set of reliable and valid indicators related to CVD prevention. The objective of this study is to assess a selection of psychometric properties such as testretest and inter-rater reliabilities as well as convergent validity.
Methods

Study design
The TRANSIT study was a three-phase participatory research program aimed at supporting continuous improvement of CVD prevention in primary care. In Phase I, members of the primary care community identified priorities for action [14] . In Phase II, these priorities were translated into a specific program of interventions and a set of 81 quality indicators was developed [12] . In Phase III, a cluster randomized controlled trial (NCT01418716) was conducted to evaluate the effectiveness of a facilitation process to implement the intervention program in interprofessional family medicine groups (FMGs) in the province of Quebec, Canada. [15] .
To assess reliability and validity, five research assistants attended a two-week training session described in Supplementary Methods. The TRANSIT indicators were documented retrospectively during the 14 months preceding the end of the TRANSIT study (t 14 ). To evaluate convergent validity, Burge et al. [8] and Institut national d'excellence en santé et en services sociaux (INESSS) indicators [6] were also applied retrospectively once the TRANSIT study was completed. The 60 TRANSIT indicators documented through medical record review were the only ones used in the psychometric analysis because their assessment could vary across time (test-retest reliability) and between evaluators (inter-rater reliability). The medical record was also the only common data source between the three sets of indicators used to assess the convergent validity.
Study population
A total of 8 FMGs, 98 clinicians and 759 patients participated in the TRANSIT study. Four FMGs used paper medical records while the other four used paper and electronic medical records (EMRs). Patients were eligible if they met the following criteria (i) were 18 years old and older; (ii) were at moderate or high risk of CVD as evaluated by the Framingham CVD risk score [16] ; (iii) had hypertension, dyslipidemia or diabetes that was either uncontrolled or for which pharmacotherapy had been initiated and (iv) had at least two other chronic diseases, excluding CVD and CVD risk factors.
Preliminary results of inter-rater reliability at baseline (n = 28 TRANSIT study patients) were used to determine the number of patients needed for the psychometric analysis. Assuming that an interrater intraclass correlation coefficient (ICC) of at least 0.7 is necessary to conclude that a tool is reliable [17] , 58 patients would be sufficient for the psychometric analysis (ICC equal to 0.81 with an 95% confidence interval [CI] ranging from 0.70 to 0.88). To increase the study's external validity, more patients were selected using specific eligibility criteria at baseline, such as: (i) FMG (16 patients/FMG); (ii) physician (minimum of four physicians/FMG); (iii) CVD risk score (eight patients at moderate risk of CVD and eight at high risk of CVD/ FMG [16] ) and (iv) CVD risk factors, such as uncontrolled hypertension (minimum of four patients/FMG), uncontrolled dyslipidemia (minimum of four patients/FMG) and uncontrolled diabetes (minimum of four patients/FMG). The characteristics of the study population were documented at baseline using information from medical records and self-administered patient questionnaires. This study was approved by the research ethics board of the Centre de santé et de services sociaux de Laval (CSSSL) (2013-2014/04-02). Every participating clinician and patient signed an informed consent form.
Test-retest reliability
The TRANSIT indicators were rated twice, two months apart, by the same evaluator (C.K.) in a subsample of 123 patients. A twomonth period between evaluations was considered sufficient to minimize overestimation of reliability due to recall bias.
Inter-rater reliability
The TRANSIT indicators were independently rated by two evaluators in a subsample of 123 patients. One rating was done by an evaluator (C.K.) and the other by other research assistants (C.P., M. J.H., V.S., V.B.).
Convergent validity
The Burge et al. and INESSS indicators were considered in the assessment of convergent validity if they complied with the following criteria: (i) evaluated through medical record review; (ii) related to similar domains of CVD prevention and (iii) applicable to more than 10% of the subsample. The selected indicators were rated by the same evaluator (C.K.) in a subsample of 123 patients. Since our assessment of the convergent validity was limited to similar domains of CVD prevention in each set of indicators, we hypothesized that the TRANSIT subscale and overall scale scores would be strongly correlated (r > 0.50) to the Burge et al.'s and the INESSS's scores. We also hypothesize that the TRANSIT indicators would be more strongly correlated to the INESSS indicators since the two sets were developed in the province of Quebec in a context of improving clinical practices in primary care.
Statistical analysis
Characteristics were described for all patients participating in the TRANSIT study and the psychometric analysis using means and standard deviations for continuous variables and numbers and proportions for categorical variables. For each patient, research assistants assessed whether care processes were compliant (yes/no) or not applicable to each indicator. For example, all indicators related to hypertension management were rated as not applicable for nonhypertensive patients at baseline. For a hypertensive patient, care processes were compliant (yes) to the indicator 'target for BP documented in the medical record' if a BP target was documented in the medical record and were not compliant (no) if no BP target was documented. For every patient, the mean compliance (number of compliant indicators/number of applicable indicators) to all indicators of a category (subscale score) and to the complete set of indicators (overall scale score) was established.
Test-retest and inter-rater reliabilities were determined by assessing correlations between administrations (test and retest) and between raters. Prevalence-adjusted bias-adjusted kappa coefficients (PABAKs) [18] were computed for each indicator, while ICCs (oneway random) and 95% CI were computed for subscale and overall scale scores. PABAKs were used because, unlike kappa coefficients, they are not influenced by prevalence and bias between raters. PABAKs values <0, between 0.00 and 0.20, between 0.21 and 0.40, between 0.41 and 0.60, between 0.61 and 0.80, and greater than 0.81 indicate poor, slight, fair, moderate, substantial and almost perfect agreement, respectively [19] . ICC values <0.5, between 0.5 and 0.75, between 0.75 and 0.9, and greater than 0.90 indicate poor, moderate, good and excellent reliability, respectively [20] . Convergent validity was determined by assessing correlations between TRANSIT, Burge et al. and INESSS scores. Pearson's correlation coefficients and P-values (α = 0.01) were computed for subscale and overall scale scores. The strength of the correlation was assessed as follow: absent (r < 0.20), weak (r = 0.20-0.34), moderate (r = 0.35-0.49), and strong (r > 0.50) [21] . All analyzes were performed using SAS version 9.1 and SPSS version 20.
Results
A total of 759 patients participated in the TRANSIT study. For the psychometric analysis, 128 patients were meant to be randomly selected from the TRANSIT study patients. However, in one participating FMG, only seven patients were at moderate risk of CVD. Thus, 127 patients followed-up by 67 physicians were randomly selected for the psychometric analysis. Of those, three withdrew and one died during the TRANSIT study, leaving a total of 123 patients in the psychometric analysis.
Characteristics of the study population
As reported in Table 1 , baseline characteristics of patients participating in the TRANSIT study and the psychometric analysis were similar in terms of age (psychometric analysis: 59.5 years versus TRANSIT study: 62.3 years), sex (53.6% versus 52.0%) and other sociodemographic and clinical characteristics. More patients in the psychometric analysis were at moderate risk of CVD (49.6% versus 16.2%). They were also more likely to have uncontrolled dyslipidemia (78.6% versus 58.3%) and less likely to have diabetes (43.1% versus 66.9%) or hypertension (71.5% versus 78.5%).
Test-retest reliability
When the indicators were applied to the subsample of patients by the same evaluator (C.K.) at a two-month interval, the percentage of concordant evaluations for each indicator varied from 89 to 100%, with PABAKs ranging from 0.77 to 1.00 (see Supplementary  Table S2 ). As reported in Table 2 , test-retest reliability, as measured by ICCs, varied from 0.95 (0.92-0.97) to 1.00 (0.99-1.00) for the subscale scores and was equal to 0.99 (0.99-0.99) for the overall scale score. ICC results indicate excellent agreement between test and retest assessments.
Inter-rater reliability
When the indicators were applied to the subsample of patients by two different evaluators (C.K. and C.P., M.J.H., V.S. or V.B.), the percentage of concordant evaluations for each indicator varied from 65 to 100%, with PABAKs ranging from 0.30 to 1.00 (see Supplementary Table S2 Tables S3 to S5 ). As reported in Table 3 , convergent validity, as measured by Pearson's correlation coefficients, varied from 0.10 (P = 0.374) to 0.91 (P < 0.001) for the subscale scores and was equal to 0.77 (P < 0.001) for the overall scale score when the TRANSIT indicators were compared to Burge et al. indicators. As reported in Table 4 , convergent validity, as measured by Pearson's correlation coefficients, varied from 0.34 (P < 0.001) to 0.73 (P < 0.001) for the subscale scores and was equal to 0.82 (P < 
Discussion
In the TRANSIT study, members of the primary care community developed a set of 81 quality indicators related to CVD prevention [12] . In this study, the reliability and the convergent validity of 60 of these indicators were evaluated. Our results suggest that testretest reliability was excellent while inter-rater reliability was good to excellent, except for one indicator with fair agreement between raters and 10 indicators with moderate agreement. Convergent validity was strong except for domains related to the management of CVD risk factors.
Reliability is an essential characteristic of any useful tool. Given the substantial number of observations needed to detect statistically significant differences, only reliable indicators are likely to be useful to evaluate quality of care with sufficient precision. Test-retest and inter-rater reliability results were excellent. Only one indicator related to changes in the medication by a clinician if the patient was dealing with poorly controlled diabetes had fair inter-rater reliability. Ten other indicators related to modifications in the patient's treatment plan and to recommendations and targets for lifestyle changes had moderate inter-rater reliability. These 11 indicators were harder to evaluate because they often relied on the rater's judgment and required thorough search in medical records. Indicators with substantial to almost perfect inter-rater reliability were mainly related to general record keeping, to references to a clinician or a group class, and to notes from a clinician. The information needed to evaluate these indicators was much more straightforward and apparent in the medical record. In primary care, few studies have evaluated the reliability of quality indicators. Liddy et al. [22] assessed the inter-rater reliability of 23 items related to CVD prevention and obtained an overall kappa statistic of 0.91 (0.90-0.92). TRANSIT indicators had better concordance between raters, with an ICC of 0.95 (0.93-0.97) for the overall scale score. Peyrot et al. [23] carried out an initial psychometric test on 12 measures related to lifestyle. The study found test-retest coefficients ranging from 0.63 to 0.97 and a correlation coefficient of 0.77 between participants' and raters' scores. Godwin et al. [24] developed 10 measures related to type II diabetes and found their test-retest reliability was greater than 0.75. The 60 TRANSIT indicators documented through medical review had better test-retest reliability, with PABAKs ranging from 0.91 to 1.00.
Although reliability is an essential characteristic, it is not sufficient; testing the validity of a tool is also necessary. Despite our attempt to select indicators related to similar domains of CVD prevention, underlying differences between the three sets of indicators influenced convergent validity results. Categories such as 'general record keeping' and 'targets and recommendations' had stronger correlation coefficients than those related to the management of hypertension, dyslipidemia, and diabetes. This is probably due to the type of indicators included in these specific categories. Indeed, while the TRANSIT research team focused on process indicators, Burge et al. and INESSS developed both process and outcome indicators.
This highlights an important question as to which type of indicator should be used to measure quality of care. Process indicators are generally accepted as the most useful for evaluating and improving quality of care because they are easier to interpret and more sensitive to changes. They can also be measured immediately and provide an opportunity to act before it is too late [25] [26] [27] [28] [29] . Outcome Table 2 Test-retest and inter-rater interclass correlation coefficients for the TRANSIT's subscale and overall scale scores Test-retest reliability (n = 123)
Inter-rater reliability (n = 123) indicators are generally used to evaluate care given by high-volume providers over long periods of time [29] . They represent the impact of care on the population's health and reflect all contributions to care [25] . Because they depend on many factors unrelated to care process, it is difficult to know with certainty whether an observed outcome is a direct consequence of a previous care process [25, 26, 29] . Members of the primary care community need to decide which type of indicator best suits their purposes. Process indicators should be used to target areas for future improvement and evaluate the effectiveness of quality improvement strategies, whereas outcome indicators should be used to assess and compare performance across organizations, as they provide information on clinical endpoints.
Limitations
Due to the sampling strategy, patients in the psychometric analysis were more likely to be at moderate risk of CVD. They were also more likely to have uncontrolled dyslipidemia and less likely to have diabetes and hypertension. However, this was done intentionally to increase the study's external validity. Only indicators documented through medical record review were used in this psychometric analysis. Medical records are a key source of information about care processes and clinical outcomes [25, 30] , but are limited by poor quality documentation [25, 27] . Finally, the findings from this study were derived from indicators based on Canadian cardiovascular treatment guidelines and, as such, might need to be adapted if they are used internationally. For instance, in the United States or Europe, members of the primary care community could choose the TRANSIT indicators that are best suited to their practice, to the structure of care, and to the available resources (e.g. EMRs) in their country.
Conclusion
The involvement of researchers, healthcare managers, primary care clinicians, patients, and family members allowed the development of a set of quality indicators that considers key elements in primary care, such as interprofessional collaboration and support lifestyle changes. This study is the first component of a complete psychometric analysis in which a selection of psychometric proprieties was assessed. Reliability results were excellent except for eleven indicators with fair to moderate agreement between raters. Convergent validity results were strong except for domains related to the management of CVD risk factors. Conducting a complete psychometric analysis of indicators related to CVD prevention could make a significant contribution to knowledge translation and decision making for quality improvement in primary care. A small set of valid and reliable indicators could be used in everyday practice and become a valuable tool to measure clinical practices. TRANSIT indicators have the potential to influence processes of care and become an interesting platform for future research linking processes to outcomes.
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